Monopoly tech platform, unproven commercialization, government approval dependent

Reported 307.7 Cr consolidated, 280 Cr standalone, PAT 33.2 Cr

280 Cr baseline; 1550 Cr implies 451% growth if linear, or H2 >>H1. Conservative label is overstated.

Machines sold but still early stage; not visible in Q1 top-line yet at material scale.

Government LED/solar projects, recurring B2G revenue. Confirmed multiple times.

Still in approval stage (ICMR/CDSCO). Prototype ready, no confirmed government orders yet.

Listed 10 July 2026 via merger with Kratos Energy (shell). New disclosure obligations and governance controls. Prior auditors/CS resigned per normal reverse-merge practice.

Added breast cancer test from C-MET in 2026. Onco tech from BARC (3 products), sickle cell from IIT Bombay now in final approval. Medtech now 55% of Q1 revenue vs. historical renewable dominance.

Machines installed at hospitals; 500+ order book reported. BEL + other OEM partners manufacturing. First dialysis center rollout planned (50 by FY27-end per guidance).

BEL manufactures dialysis machine on cost-plus basis. IIT partnership for sickle cell R&D done, product approval pending. Licensed monopolistic tech from govt institutions; scale via government orders (sickle cell) and direct sales (dialysis).

Onco: preventive healthcare + existing cancer patients (₹20-30K biopsy/PET replacement, our test affordable). Sickle cell: 18 Cr population affected, government mass testing program. FY28 guidance = >20% growth over FY27 (1550 Cr), possibly more with product launches. No confirmed govt POs yet; will come post-approval via tender.

Renewable energy: ~₹3000 Cr order book. Dialysis: >500 machines spread across exports and domestic.

Not an acquisition; new company incorporated for planned business. Disclosure to follow.

No confirmed orders yet; once approved, government will issue tender and set price. Budget assumption very conservative; no expected revenue impact.

Cost ~4.5L, selling price ~7.5L. No JV; OEM model via BEL and other partners to avoid capital intensity. Will set up own capex once scale stabilizes. Very competitive with foreign dialysis machines. AI-based, unique, took 13 years to develop.

Feasibility study underway. Pilot likely Q3 or Q1 FY28. May acquire small hospital vs. greenfield. Expect update after Q2 guidance. Too early to commit March 2027 target.

Q1: 55% IVD/Medtech, 45% renewable energy.

Healthcare/Medtech: ~20% EBITDA (high-margin, monopolistic tech, less competition). Renewable: ~11% EBITDA (competitive, traditional business).

By FY28: >₹2000 Cr revenue; PAT margin 10-11% conservative basis.

Healthcare attracts focus (monopolistic tech, high growth potential). Renewable: competitive, decent order book (₹3000 Cr), RESCO model profitable at 4.95 Rs/unit. Both needed; Medtech will drive margin improvement.

Assumes ₹280 Q1 baseline scales with H2 >> H1 (B2G seasonality) + new product launches Q4. Product approvals + government order timing critical. No prior year baseline provided (new listed entity post-merger).

Q1 delivered 10.6% NPM. FY28 target same level, which is conservative if high-margin medtech (20% EBITDA) ramps as planned. But assumes product launches on track.

Hospital/cancer center capex mentioned (feasibility underway) but no numbers or timeline confirmed. 50 dialysis centers by FY27-end assumes incremental operating capex, not stated.

Onco Spot, TB Truth, sickle cell test, breast cancer test all await ICMR/CDSCO approval. No confirmed timeline. Q4 FY27 launch is aspirational.

Sickle cell revenue model assumes ₹3000 Cr govt elimination program will purchase Lord's Mark test kits at budgeted price. No PO signed; tender process, pricing, volume unconfirmed.

Dialysis centers (50 by FY27-end), Onco platforms, sickle cell test, hospital/cancer center build-out all expected in H2 FY27. Company is 28-year-old but medtech/healthcare service delivery is new. Recently listed; governance/board scrutiny may slow decisions.

Dialysis machine is capital-intensive. Foreign players already entrenched; Lord's Mark claims 13-year development and AI-based advantage. 500+ order book is early-stage. Execution on 50 dialysis centers will face competition from established diagnostic/dialysis providers.

Listed 10 July 2026 via reverse merger with Kratos Energy shell. Promoter stake 80%; must dilute to 75% per SEBI norms. Decision on OFS vs. rights issue pending. Prior auditors/CS resigned per reverse-merge practice (flagged in Q&A but explained).